TRANSCAN-3: Joint Transnational Call for Proposals 2021 (JTC 2021)

Tous les appels à projets

The ERA-NET TRANSCAN-3 , in continuity of the preceding ERA-NET TRANSCAN-2, aims to promote a transnational collaborative approach between scientific teams in demanding areas of translational cancer research, to produce significant results of higher quality and impact, and share data and infrastructures.

The first Joint Transnational Call for Proposals 2021 (JTC 2021), with the contribution of the European Commission, will focus on:

"Next generation cancer immunotherapy: targeting the tumour microenvironment"

Despite advances in immunotherapies, obstacles and challenges, including limited response rates, the inability to predict clinical efficacy, and potential side effects such as autoimmune reactions or cytokine release syndromes, remain and hinder further applications of immunotherapies in clinics. Thus, a deeper understanding of the TME, able to dissect distinct classes and subclasses of it, is essential for deciphering new mechanisms of immunotherapies, defining new predictive biomarkers, and identifying novel therapeutic targets.

This topic, at the intersection of laboratory and clinical research in immuno-oncology, will comprise two general aims, which concur to the possible clinical applications:

Aim 1: Identification and validation of TME subclasses and their contribution to the resistance mechanisms: Translational research using tumour samples collected from retrospective and/or prospective cohorts of patients.
Aim 2: Targeting TME to improve efficacy of immunotherapy in human patients.